SCHEMBL2942222

SCHEMBL2942222

O=C(NS(=O)(=O)c1ccc(Cl)c([N+](=O)[O-])c1)c1ccc(C2=CCCCC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.51
ALDH1A1 P00352 1/20 0.51
MAPK1 P28482 1/20 0.51
LMNA P02545 2/20 0.47
HTT P42858 1/20 0.47
VCAM1 P19320 4/20 0.46
FLT1 P17948 4/20 0.46
FLT4 P35916 4/20 0.46
KDR P35968 4/20 0.46
MCL1 Q07820 2/20 0.44
BCL2 P10415 2/20 0.43
BCL2L1 Q07817 2/20 0.43
SLC25A1 P53007 1/20 0.43
FBP1 P09467 1/20 0.42
SLC10A2 Q12908 1/20 0.42
SLC10A1 Q14973 1/20 0.42
SLC10A6 Q3KNW5 1/20 0.42
NPBWR1 P48145 1/20 0.41
MCHR1 Q99705 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2948245 0.81 BCL2L1 (0.59) VCAM1FLT1FLT4KDRMCL1
SCHEMBL2943629 0.79 BCL2L1 (0.46) MAPTALDH1A1MCL1BCL2BCL2L1
SCHEMBL29855771 0.79 BCL2L1 (0.50) MAPTALDH1A1HTTBCL2BCL2L1
SCHEMBL2949631 0.79 BCL2L1 (0.46) MAPTALDH1A1MCL1BCL2BCL2L1
SCHEMBL2953271 0.79 BCL2L1 (0.46) MAPTALDH1A1MCL1BCL2BCL2L1
SCHEMBL2953273 0.79 BCL2L1 (0.46) MAPTALDH1A1MCL1BCL2BCL2L1
SCHEMBL2943530 0.79 BCL2L1 (0.55) MCL1BCL2BCL2L1
SCHEMBL2943850 0.77 BCL2L1 (0.74) MCL1BCL2BCL2L1
SCHEMBL31198330 0.76 BCL2 (0.48) MAPTALDH1A1HTTMCL1BCL2
SCHEMBL31525125 0.76 BCL2 (0.50) BCL2BCL2L1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7754886-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2010-07-13 US disclosed
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2009-05-28 US disclosed
US-7504512-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-03-17 US disclosed
EP-1318978-B1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2006-02-08 EP disclosed
US-20040192681-A1 N-acylsulfonamide apoptosis promoters ABBVIE INC. 2004-09-30 US disclosed
US-6720338-B2 BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL ABBOTT LABORATORIES 2004-04-13 US disclosed
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters ABBVIE INC. 2002-07-04 US disclosed
US-20020055631-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2002-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 MAPT 4851/4885ALDH1A1 2651/4885MAPK1 2657/4885
US-20020055631-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 MAPT 4830/4885ALDH1A1 2460/4885MAPK1 2730/4885
US-20040192681-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 MAPT 4851/4885ALDH1A1 2651/4885MAPK1 2657/4885
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BCOR MAPT 4806/4885ALDH1A1 3404/4885MAPK1 4010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.